PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.21%
R&D growth while AXSM reduces spending. John Neff would investigate strategic advantage.
-38.56%
G&A reduction while AXSM shows 4.76% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-22.93%
Other expenses reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine efficiency.
-7.06%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-7.06%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-22.93%
D&A reduction while AXSM shows 3.81% growth. Joel Greenblatt would examine efficiency.
7.02%
EBITDA growth 50-75% of AXSM's 9.80%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
7.06%
Similar operating income growth to AXSM's 6.72%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
148.79%
Other expenses growth above 1.5x AXSM's 59.19%. Michael Burry would check for concerning trends.
10.36%
Pre-tax income growth 1.25-1.5x AXSM's 9.19%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.36%
Net income growth 1.25-1.5x AXSM's 9.19%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
28.30%
EPS growth exceeding 1.5x AXSM's 10.00%. David Dodd would verify competitive advantages.
28.30%
Diluted EPS growth exceeding 1.5x AXSM's 10.00%. David Dodd would verify competitive advantages.
24.68%
Share count reduction below 50% of AXSM's 0.16%. Michael Burry would check for concerns.
24.68%
Diluted share reduction below 50% of AXSM's 0.16%. Michael Burry would check for concerns.